BioSpace News Archive

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.

Illumina, Inc. posted a stewardship-focused presentation for investors on the Events & Presentations section of its investor relations website, investor.illumina.com, on Wednesday, October 11, 2023.

Paradigm-shifting neuromodulation company, StimAire, has completed its first clinical trial in Australia.

Scholar Rock announced it plans to advance SRK-439, a novel investigational myostatin inhibitor for the treatment of obesity towards an investigational new drug application submission in 2025.

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird 2023 Global Industrial Conference on Wednesday, November 8, 2023, in Chicago, Illinois.

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases.

New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria.

Lucy Therapeutics (LucyTx) has secured new funding from the International Rett Syndrome Foundation (IRSF) to invest in pioneering treatments for children and adults living with Rett syndrome, and to grow LucyTx’s groundbreaking treatment platform.

Lineage Cell Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,746,324, entitled “Large Scale Production of Retinal Pigment Epithelial Cells”.

IMIDomics Inc. today announced a strategic license and collaboration agreement with the University of Barcelona (UB).